Zhejiang Hisun Pharmaceutical Co Ltd

Zhejiang Hisun maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.34, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.93, suggesting that its current liabilities slightly exceed its current assets. Free cash flow stands at 803.35 million CNY, which supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 6.28% and a return on assets (ROA) of 3.59%, both of which are below the industry median for pharmaceutical firms. The company's net income of 540.71 million CNY is supported by a gross profit of 4.69 billion CNY, but its operating income of 867.09 million CNY suggests moderate operating leverage. Geographically, Zhejiang Hisun's revenue is concentrated in China, with no disclosed international segments. The company's exposure to domestic regulatory and economic conditions is high, and its revenue concentration in a single market increases vulnerability to local policy shifts or economic downturns. The company's growth trajectory is modest, with no disclosed revenue growth rates or forward-looking guidance. Analysts have assigned a mean price target of 7.50 CNY, with all estimates converging at the same value, indicating a neutral outlook with no strong buy or sell signals. Risk factors include a negative net cash position after subtracting total debt, which could constrain the company's ability to fund operations or investments without external financing. The risk of dilution is assessed as low, with no recent signs of share issuance or at-the-market (ATM) programs. Recent filings and transcripts do not indicate any material events or strategic shifts. The company's capital expenditure of -376.40 million CNY suggests a reduction in investment in physical assets, which may reflect a focus on cost control or a shift toward intangible assets.